GRI Bio, Inc.
NCM: GRILive Quote
📈 ZcoreAI Score
Our AI model analyzes GRI Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GRI Z-Score →About GRI Bio, Inc.
Healthcare
Biotechnology
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
📊 Fundamental Analysis
GRI Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -238.2%, which indicates that capital utilization is currently under pressure.
At a current price of $2.45, GRI currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $2.10 - $80.36).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$3.54M
Trailing P/E
--
Forward P/E
-0.31
Beta (5Y)
-1.24
52W High
$80.36
52W Low
$2.10
Avg Volume
395K
Day High
Day Low